Keywords: Teva, USA, FDA, Neurtoval, Neupogen, Neutropenia, OncoGenex, Prostate cancer, Custirsen

US FDA delays Teva’s Neutroval BLA; custirsen enters second Ph III trial

Article | 04 October 2010

Print This

The US Food and Drug Administration has issued a Complete Response Letter for the Biologic License Application for Israeli drugmaker ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in